Outcomes of Mitral Valve Surgery in Patients Affected by Rheumatic Heart Disease
Overview
rheumatic heart disease remains the majority valvular disease in low and middle income countries, which mostly affected mitral valve, surgical treatment is the most effective strategy to improve the outcomes of middle or late-stage RHD patient, however, whether mitral valve repair surgery is superior to replacement or other evolving interventional device remains controversial, this study aims to investigate the results of repair surgery compared with replacement or other treatment strategy from international multicenters.
Full Title of Study: “Multicenter Results of Mitral Valve Surgery in Patients With Rheumatic Heart Disease”
Study Type
- Study Type: Observational [Patient Registry]
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: January 1, 2024
Interventions
- Device: mitral valve repair
- different repair techniques to construct rheumatic mitral valve lesion
Clinical Trial Outcome Measures
Primary Measures
- all-cause mortality
- Time Frame: 2011-2024
- death from any cause
Participating in This Clinical Trial
Inclusion Criteria
- 1、rheumatic heart disease 2、mitral valve disease 3、combined with other heart valve disease(aortic valve, tricuspid valve, pulmonary valve) 4、patients underwent initial mitral valve surgery or intervention Exclusion Criteria:
- 1、congenital heart disease degenerative heart valve disease 2、isolated aortic valve or tricuspid valve, pulmonary valve disease( doesn't affect mitral valve ) 3、patients received more than 1 time mitral valve operation
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Beijing Anzhen Hospital
- Provider of Information About this Clinical Study
- Principal Investigator: Xu Meng, NO.9 department of Cardiac surgery center – Beijing Anzhen Hospital
- Overall Official(s)
- xu meng, MD, Principal Investigator, Beijing Anzhen Hospital
- Overall Contact(s)
- xu meng, MD, mengxu191116@163.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.